Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inventiva (DE:6IVA)
STUTTGART:6IVA
Inventiva (6IVA) Stock Price & Analysis
0 Followers
6IVA Stock Chart & Stats
Day’s Range€2.7 - €3.12
52-Week Range― - ―
Previous Close€3
Volume0.00
Average Volume (3M)N/A
Market Cap
$165.78M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Sep 25, 2024EPS Estimate
-€1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.86Price Target Upside504.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Inventiva News
PremiumCompany Announcements
Inventiva SA ADR Announces Optimistic 2023 Results
PremiumCompany Announcements
Inventiva’s LEGEND Trial Shows Promising Results
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive interim results from the LEGEND trial highlight lanifibranor's significant reductions in Hemoglobin A1c and its cardiometabolic benefits.
Drug Development ProgressPatient screening for the pivotal NATiV3 trial has resumed, ensuring study timelines remain on track.
Therapeutic PotentialLanifibranor demonstrates potential to be a leading therapy for T2D patients with MASH, with substantial improvements in liver fibrosis observed in the Phase 2b NATIVE study.
Bears Say
Clinical Trial SetbackThe enrollment pause in the Phase III NATiV3 study was due to a reported treatment-related serious adverse reaction.
Financial Health ConcernThe company has a limited cash runway, with an annualized cash burn rate that suggests only approximately 0.6 years of cash left.
Product Launch DelayThe anticipated launch year of Lani in the U.S. market has been pushed back.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
9.16% Other Institutional Investors
90.84% Public Companies and
Individual Investors
6IVA FAQ
What was Inventiva’s price range in the past 12 months?
Currently, no data Available
What is Inventiva’s market cap?
Currently, no data Available
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Sep 25, 2024 which is in 143 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Mar 27, 2024. The company reported -€0.598 earnings per share for the quarter, beating the consensus estimate of -€0.644 by €0.046.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -€1.06.
How many shares outstanding does Inventiva have?
Currently, no data Available
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -€0.598 in its last earnings report, beating expectations of -€0.644. Following the earnings report the stock price went down -1.852%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in DE:6IVA
---
Inventiva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€18.86 (504.48% Upside)
€18.86 (504.48% Upside)
Blogger Sentiment
Bullish
DE:6IVA Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.62%
12-Months-Change
Fundamentals
Return on Equity
-1928.18%
Trailing 12-Months
Asset Growth
-38.16%
Trailing 12-Months
Company Description
Inventiva
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis and rare diseases. All the company's operations are located in France.
---
6IVA Stock 12 Months Forecast
Average Price Target
€18.86
▲(504.48% Upside)
Technical Analysis
Best Analysts Covering 6IVA
1 Year
1 Year Success Rate
3/22 ratings generated profit
1 Year Average Return
-24.80%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 13.64% of your transactions generating a profit, with an average return of -24.80% per trade.
---